Mike has led the CMC development activities for Allergan's biologics products for the past 3 years. He has over 19 years of experience developing a diverse portfolio of biological and cell therapy products. Mike earned his B.S. in Biology from New Mexico Institute of Mining and Technology and his Ph.D. from University of Florida. Previous roles include Vice President, Biologicals at Eisai Inc. and Vice President, Development at RenaMed, a cell therapy company engaged in development of a cell therapy device targeted to treat acute kidney injury. Before RenaMed he held positions of increasing responsibility at biotechnology companies including Cambridge NeuroScience, BioTransplant and Epic Therapeutics, a subsidiary of Baxter engaged in drug delivery technology development.